MARKET

CLSN

CLSN

Celsion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5795
-0.0095
-1.61%
Opening 13:59 10/22 EDT
OPEN
0.6100
PREV CLOSE
0.5890
HIGH
0.6100
LOW
0.5652
VOLUME
456.44K
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
0.5595
MARKET CAP
19.38M
P/E (TTM)
-0.7747
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Celsion Corporation Issues Letter To Stockholders
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies   LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion
Benzinga · 10/12 12:06
Horizon Technology Finance Provides Third Quarter 2020 Portfolio Update
Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon," "We," "Our" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare
PR Newswire · 10/07 21:15
Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study
GlobeNewswire · 09/08 13:35
Celsion Corporation Restructures Strategic Loan Facility
ompletes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion's Capitalization New Agreement Ensures A Strong Balance Sheet and Additional Operating
Benzinga · 09/02 12:07
Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2020 Results - Earnings Call Transcript
Celsion Corporation (NASDAQ:CLSN) Q2 2020 Results Conference Call August 14, 2020 11:00 AM ET Company Participants Kim Golodetz - IR, LHA Investor Relations Michael Tardugno - Chairman, President and Chief Executive Officer Jeffrey Church - Senior Vice President and Chief Financial Officer Nicholas Borys - Chief Medical Officer Conference Call Participants Justin Kim - Oppenheimer Raj Kumar - Brookline Capital Markets Presentation Operator Good morning.
Seeking Alpha - Transcript · 08/14 20:24
Celsion: Q2 Earnings Insights
Benzinga · 08/14 13:48
Celsion Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $125.00K Beat $80.00K Estimate
Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 37.93 percent increase over losses of $(0.29) per share from the
Benzinga · 08/14 12:04
Celsion EPS misses by $0.03, revenue in-line
Celsion (CLSN): Q2 GAAP EPS of -$0.18 misses by $0.03.Revenue of $0.13M in-line (flat Y/Y).Shares +1.83% PM.Press Release
Seekingalpha · 08/14 12:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSN. Analyze the recent business situations of Celsion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSN stock price target is 6.00 with a high estimate of 9.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 4.18M
% Owned: 12.48%
Shares Outstanding: 33.44M
TypeInstitutionsShares
Increased
10
2.00M
New
26
-375.70K
Decreased
2
3.58K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.14%
Pharmaceuticals & Medical Research
+0.03%
Key Executives
Chief Financial Officer/Senior Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Senior Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Independent Director
Donald Braun
Independent Director
Pok Yu Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
Independent Director
Alberto Martinez
Independent Director
Andreas Voss
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLSN
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Celsion Corporation stock information, including NASDAQ:CLSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSN stock methods without spending real money on the virtual paper trading platform.